131 related articles for article (PubMed ID: 17658251)
21. In vitro characterization of hepatocyte growth factor release from PHBV/PLGA microsphere scaffold.
Zhu XH; Wang CH; Tong YW
J Biomed Mater Res A; 2009 May; 89(2):411-23. PubMed ID: 18431776
[TBL] [Abstract][Full Text] [Related]
22. Flurbiprofen PLGA-PEG nanospheres: role of hydroxy-β-cyclodextrin on ex vivo human skin permeation and in vivo topical anti-inflammatory efficacy.
Vega E; Egea MA; Garduño-Ramírez ML; García ML; Sánchez E; Espina M; Calpena AC
Colloids Surf B Biointerfaces; 2013 Oct; 110():339-46. PubMed ID: 23743255
[TBL] [Abstract][Full Text] [Related]
23. Leucinostatin-A loaded nanospheres: characterization and in vivo toxicity and efficacy evaluation.
Ricci M; Blasi P; Giovagnoli S; Perioli L; Vescovi C; Rossi C
Int J Pharm; 2004 May; 275(1-2):61-72. PubMed ID: 15081138
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of gene transfection into human dendritic cells using cationic PLGA nanospheres with a synthesized nuclear localization signal.
Kanazawa T; Takashima Y; Murakoshi M; Nakai Y; Okada H
Int J Pharm; 2009 Sep; 379(1):187-95. PubMed ID: 19555751
[TBL] [Abstract][Full Text] [Related]
25. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice.
Murata N; Takashima Y; Toyoshima K; Yamamoto M; Okada H
J Control Release; 2008 Mar; 126(3):246-54. PubMed ID: 18215787
[TBL] [Abstract][Full Text] [Related]
26. Optimization of maghemite-loaded PLGA nanospheres for biomedical applications.
Silva MF; Winkler Hechenleitner AA; de Oliveira DM; Agüeros M; Peñalva R; Irache JM; Pineda EA
Eur J Pharm Sci; 2013 Jun; 49(3):343-51. PubMed ID: 23602998
[TBL] [Abstract][Full Text] [Related]
27. PLGA-based drug delivery systems: importance of the type of drug and device geometry.
Klose D; Siepmann F; Elkharraz K; Siepmann J
Int J Pharm; 2008 Apr; 354(1-2):95-103. PubMed ID: 18055140
[TBL] [Abstract][Full Text] [Related]
28. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
29. pH-sensitive polymer nanospheres for use as a potential drug delivery vehicle.
Jung J; Lee IH; Lee E; Park J; Jon S
Biomacromolecules; 2007 Nov; 8(11):3401-7. PubMed ID: 17939711
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Use of 3β-[N-(N',N'-Dimethylaminoethane) Carbamoyl] Cholesterol-Modified PLGA Nanospheres as Gene Delivery Vehicles for Spinal Cord Injury.
Gwak SJ; Yun Y; Yoon DH; Kim KN; Ha Y
PLoS One; 2016; 11(1):e0147389. PubMed ID: 26824765
[TBL] [Abstract][Full Text] [Related]
31. Prolonged analgesic effect of PLGA-encapsulated bee venom on formalin-induced pain in rats.
Jeong I; Kim BS; Lee H; Lee KM; Shim I; Kang SK; Yin CS; Hahm DH
Int J Pharm; 2009 Oct; 380(1-2):62-6. PubMed ID: 19577620
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres.
Zolnik BS; Burgess DJ
J Control Release; 2008 Apr; 127(2):137-45. PubMed ID: 18282629
[TBL] [Abstract][Full Text] [Related]
33. The effect of poly(D,L-lactide-co-glycolide) microparticles with polyelectrolyte self-assembled multilayer surfaces on the cross-presentation of exogenous antigens.
Yang YW; Hsu PY
Biomaterials; 2008 Jun; 29(16):2516-26. PubMed ID: 18329708
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of continuous flow nanosphere formation by controlled microfluidic transport.
Laulicht B; Cheifetz P; Mathiowitz E; Tripathi A
Langmuir; 2008 Sep; 24(17):9717-26. PubMed ID: 18681411
[TBL] [Abstract][Full Text] [Related]
35. Development of highly porous large PLGA microparticles for pulmonary drug delivery.
Yang Y; Bajaj N; Xu P; Ohn K; Tsifansky MD; Yeo Y
Biomaterials; 2009 Apr; 30(10):1947-53. PubMed ID: 19135245
[TBL] [Abstract][Full Text] [Related]
36. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
37. Topical delivery of urea encapsulated in biodegradable PLGA microparticles: O/W and W/O creams.
Haddadi A; Aboofazeli R; Erfan M; Farboud ES
J Microencapsul; 2008 Sep; 25(6):379-86. PubMed ID: 18465299
[TBL] [Abstract][Full Text] [Related]
38. Tyrosine-derived nanospheres for enhanced topical skin penetration.
Sheihet L; Chandra P; Batheja P; Devore D; Kohn J; Michniak B
Int J Pharm; 2008 Feb; 350(1-2):312-9. PubMed ID: 17897801
[TBL] [Abstract][Full Text] [Related]
39. The effect of formulation variables on the characteristics of insulin-loaded poly(lactic-co-glycolic acid) microspheres prepared by a single phase oil in oil solvent evaporation method.
Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
Colloids Surf B Biointerfaces; 2009 Nov; 74(1):340-9. PubMed ID: 19717287
[TBL] [Abstract][Full Text] [Related]
40. PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen-in vitro, ex vivo and in vivo characterization.
Sánchez-López E; Egea MA; Cano A; Espina M; Calpena AC; Ettcheto M; Camins A; Souto EB; Silva AM; García ML
Colloids Surf B Biointerfaces; 2016 Sep; 145():241-250. PubMed ID: 27187188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
